Company Filing History:
Years Active: 2021-2024
Title: Cornelia Bruenn: Innovator in Biological Activity Determination
Introduction
Cornelia Bruenn is a notable inventor based in Frankfurt-am-Main, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of methods for determining biological activity in cells.
Latest Patents
Cornelia Bruenn holds two patents, with her latest invention focusing on the means and methods for the determination of the biological activity of BoNT/E in cells. This invention involves a polyclonal or monoclonal antibody that specifically binds to BoNT/E-cleaved SNAP-25. The method includes several steps, such as incubating susceptible cells with BoNT/E, fixing the cells, and using capture and detection antibodies to quantify the biological activity of BoNT/E in those cells. Additionally, the invention provides a kit for carrying out this method.
Career Highlights
Cornelia Bruenn is associated with Merz Pharma GmbH & Co. KGaA, where she applies her expertise in biotechnology and innovation. Her work has contributed to advancements in understanding the biological mechanisms of toxins and their effects on cellular functions.
Collaborations
Some of her notable coworkers include Gerd J. Mander and Harold V. Taylor, who have collaborated with her on various projects within the field.
Conclusion
Cornelia Bruenn's innovative work in the determination of biological activity has the potential to impact various applications in biotechnology and medicine. Her contributions continue to advance the understanding of cellular responses to toxins.